ES2161231T3 - Compuestos heterociclicos como antagonistas de bradiquinina. - Google Patents

Compuestos heterociclicos como antagonistas de bradiquinina.

Info

Publication number
ES2161231T3
ES2161231T3 ES94106486T ES94106486T ES2161231T3 ES 2161231 T3 ES2161231 T3 ES 2161231T3 ES 94106486 T ES94106486 T ES 94106486T ES 94106486 T ES94106486 T ES 94106486T ES 2161231 T3 ES2161231 T3 ES 2161231T3
Authority
ES
Spain
Prior art keywords
hydrogen
alkilo
halogen
optionally
bradiquinina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94106486T
Other languages
English (en)
Inventor
Teruo Oku
Hiroshi Kayakiri
Shigeki Satoh
Yoshito Abe
Yuki Sawada
Takayuki Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939308804A external-priority patent/GB9308804D0/en
Priority claimed from GB939318929A external-priority patent/GB9318929D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2161231T3 publication Critical patent/ES2161231T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UN COMPUESTO DE LA FORMULA: EN LA QUE X1 ES N O C R2 ES HALOGENO; R3 ES HIDROGENO, NITRO, AMINO OPCIONALMENTE TENIENDO SUSTITUYENTE(S) O UN GRUPO HETEROCICLICO OPCIONALMENTE TENIENDO ADECUADOS SUSTITUYENTE(S); R4 Y R5 SON CADA UNO HIDROGENO O HALOGENO; R6 Y R8 SON CADA UNO HIDROGENO, HALOGENO, ALKILO INFERIOR, HIDROXI, ALKILTIO INFERIOR, AMINO OPCIONALMENTE SUSTITUIDO CON ALKILO INFERIOR, O ALKOXI INFERIOR OPCIONALMENTE SUSTITUIDO CON UN SUSTITUYENTE SELECCIONADO ENTRE EL GRUPO FORMADO POR HIDROXI, ALKOXI INFERIOR, AMINO, ALKILAMINO INFERIOR Y OPCIONALMENTE SUSTITUIDO CON ALKOXI INFERIOR; R7 ES HIDROGENO O ALKILO INFERIOR; A ES ALKILENO INFERIOR; Y Q ES O O N DONDE R9 ES HIDROGENO O ACILO, SIEMPRE QUE R3 NO SEA HIDROGENO, CUANDO X1 ES C SMOS FARMACEUTICAMENTE ACEPTABLES, PROCESOS PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN.3
ES94106486T 1993-04-28 1994-04-26 Compuestos heterociclicos como antagonistas de bradiquinina. Expired - Lifetime ES2161231T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939308804A GB9308804D0 (en) 1993-04-28 1993-04-28 New hetrocyclic compounds
GB939318929A GB9318929D0 (en) 1993-09-13 1993-09-13 New heterocyclic compounds

Publications (1)

Publication Number Publication Date
ES2161231T3 true ES2161231T3 (es) 2001-12-01

Family

ID=26302825

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94106486T Expired - Lifetime ES2161231T3 (es) 1993-04-28 1994-04-26 Compuestos heterociclicos como antagonistas de bradiquinina.

Country Status (16)

Country Link
US (4) US5563162A (es)
EP (1) EP0622361B1 (es)
JP (1) JP3346437B2 (es)
KR (1) KR100329469B1 (es)
CN (1) CN1043344C (es)
AT (1) ATE206412T1 (es)
AU (1) AU680870B2 (es)
CA (1) CA2122236C (es)
DE (1) DE69428476T2 (es)
DK (1) DK0622361T3 (es)
ES (1) ES2161231T3 (es)
HU (1) HU223140B1 (es)
IL (1) IL109395A (es)
PH (1) PH30752A (es)
PT (1) PT622361E (es)
RU (1) RU2135478C1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
DE4345062A1 (de) * 1993-12-31 1995-07-13 Hoechst Ag Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von Viruserkrankungen
WO1996004251A1 (fr) 1994-08-03 1996-02-15 Fujisawa Pharmaceutical Co., Ltd. Compose heterocyclique
ES2218554T3 (es) * 1994-10-27 2004-11-16 Fujisawa Pharmaceutical Co., Ltd. Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina.
DE19517051A1 (de) * 1995-05-10 1996-11-14 Hoechst Ag 1-Fluor-6,7-dihydro-5H-isochinolin-8-on-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
FR2735128B1 (fr) * 1995-06-07 1997-07-25 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, leur procede de preparation et utilisation en therapeutique.
FR2737892B1 (fr) * 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
JPH11514361A (ja) * 1995-10-16 1999-12-07 藤沢薬品工業株式会社 Ｈ＋−ＡＴＰａｓｅとしての複素環式化合物
FR2743073B1 (fr) * 1995-12-29 1998-02-20 Fournier Ind & Sante Nouveaux composes de 1-benzenesulfonylpyrrolidine, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) * 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) * 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) * 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19612067A1 (de) * 1996-03-27 1997-10-02 Hoechst Ag Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen
AUPN952696A0 (en) * 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
EP0808627A2 (de) * 1996-05-22 1997-11-26 Hoechst Aktiengesellschaft Verwendung nicht-peptidischer Bradykinin-Antagonisten zur Behandlung und Prävention von chronisch-fibrogenetischen Lebererkrankungen, akuten Lebererkrankungen und den damit verbundenen Komplikationen
DE19620508A1 (de) * 1996-05-22 1997-11-27 Hoechst Ag Schwefelenthaltende heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2751650B1 (fr) * 1996-07-24 1998-10-09 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
DK0835659T3 (da) * 1996-10-14 2005-04-18 Aventis Pharma Gmbh Anvendelse af ikke-peptidiske antagonister for bradykinin til fremstilling af lægemidler til behandling og forebyggelse af Alzheimer's sygdom
FR2756562B1 (fr) * 1996-12-04 1999-01-08 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
AU6422098A (en) * 1997-03-24 1998-10-20 Kyowa Hakko Kogyo Co. Ltd. Benzene derivatives
DE19712960A1 (de) * 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
FR2765222B1 (fr) * 1997-06-27 1999-12-31 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
HUP0104110A3 (en) * 1998-10-21 2003-01-28 Astellas Pharma Inc Chuo Ku Vitreous form of known bradykinin antagonist and medicament containing it
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US7105172B1 (en) 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
US6699486B1 (en) 1999-11-18 2004-03-02 Bolla Corporation Treatment or prevention of photoaging and skin cancer
WO2002012228A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Cinnoline compounds
CA2481855A1 (en) 2002-04-10 2003-10-23 Ortho-Mcneil Pharmaceutical, Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
EP1914236A1 (en) 2002-04-10 2008-04-23 Ortho-McNeil Pharmaceutical, Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
CA2483573A1 (en) 2002-05-03 2003-11-13 Elan Pharmaceuticals, Inc. Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
KR101128065B1 (ko) * 2004-05-26 2012-04-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
EP1808432B1 (en) 2004-10-26 2010-02-24 Eisai R&D Management Co., Ltd. Amorphous form of cinnamide compound
WO2007058304A1 (ja) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド化合物の塩またはそれらの溶媒和物
WO2007058305A1 (ja) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド誘導体の製造方法
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
BRPI0618814A2 (pt) * 2005-11-24 2014-04-29 Eisai R&D Man Co Ltd Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
CA2652484A1 (en) * 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. Heterocyclic type cinnamide derivative
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
CL2008000582A1 (es) 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
CA2687262A1 (en) * 2007-05-16 2008-11-20 Naoyuki Shimomura One-pot production process for cinnamide derivative
MX2009012847A (es) * 2007-06-13 2009-12-08 Bristol Myers Squibb Co Analogos dipeptidicos como inhibidores de factores de coagulacion.
US8513422B2 (en) 2007-08-31 2013-08-20 Astellas Pharma Inc. Piperidine derivative
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
US20100317860A1 (en) * 2008-01-28 2010-12-16 Ikuo Kushida Crystalline cinnamide compounds or salts thereof
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
MX2015012650A (es) * 2013-03-14 2016-06-21 Shire Human Genetic Therapies Metodos para el tratamiento de angioedema mediado receptores debradicinina b2.
DK3341367T3 (da) * 2015-08-27 2021-04-12 Pfizer Bicyklisk-fusionerede heteroaryl- eller arylforbindelser som irak4-modulatorer
IL274883B2 (en) 2017-11-24 2023-11-01 Pharvaris Netherlands B V BRADYKININ B2 receptor antagonists
AR118983A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
AR118982A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
CN113717079B (zh) * 2021-09-30 2023-03-31 内蒙古康普药业有限公司 一种甲氧氯普胺双胺新杂质的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3682927A (en) * 1968-06-15 1972-08-08 Massimo Carissimi 5,7-bichloro-8-hydroxy-2-acetylamino quinoline
EP0138773B1 (de) * 1983-10-18 1990-08-29 Ciba-Geigy Ag Verwendung von Chinolinderivaten zum Schützen von Kulturpflanzen
DE3617183A1 (de) * 1985-11-16 1987-05-27 Bayer Ag Substituierte benzylether
US5202336A (en) * 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5294622A (en) * 1988-01-29 1994-03-15 Dowelanco Substituted quinolines and cinnolines
US5212182A (en) * 1990-10-03 1993-05-18 American Home Products Corpooration Substituted quinolinyl- and naphthalenylbenzamides or benzylamines and related compounds useful as analgesics
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5574042A (en) * 1992-11-02 1996-11-12 Fujisawa Pharmaceutical Co., Ltd Imidazo [1,2-a] pyridines and their pharmaceutical use
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
AU2985499A (en) 1998-04-03 1999-10-25 Alcon Laboratories, Inc. Non-peptide bradykinin receptor antagonists for use in treating ophthalmic diseases and disorders

Also Published As

Publication number Publication date
IL109395A (en) 1998-09-24
CA2122236C (en) 2007-02-13
US5708173A (en) 1998-01-13
PT622361E (pt) 2002-03-28
HU9401221D0 (en) 1994-08-29
JPH072780A (ja) 1995-01-06
IL109395A0 (en) 1994-07-31
DK0622361T3 (da) 2001-12-03
RU2135478C1 (ru) 1999-08-27
DE69428476D1 (de) 2001-11-08
ATE206412T1 (de) 2001-10-15
KR100329469B1 (ko) 2003-01-09
EP0622361A1 (en) 1994-11-02
JP3346437B2 (ja) 2002-11-18
EP0622361B1 (en) 2001-10-04
CN1097417A (zh) 1995-01-18
PH30752A (en) 1997-10-17
US6169095B1 (en) 2001-01-02
HU223140B1 (hu) 2004-03-29
DE69428476T2 (de) 2002-05-08
AU680870B2 (en) 1997-08-14
CA2122236A1 (en) 1994-10-29
US5922711A (en) 1999-07-13
CN1043344C (zh) 1999-05-12
HUT70493A (en) 1995-10-30
AU6052594A (en) 1994-11-03
US5563162A (en) 1996-10-08

Similar Documents

Publication Publication Date Title
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
ES2175350T3 (es) Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
CO4910132A1 (es) Agonistas adrenergicos selectivos de beta 3
ES2159738T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
ES2064310T3 (es) Procedimiento para preparar compuestos de imidazopiridina.
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
ES2194937T3 (es) Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina.
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
ES2059327T3 (es) Derivados de tetrahidronaftaleno y de indano, obtencion de los mismos y utilizacion en preparados farmaceuticos.
ECSP941156A (es) 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
AR011229A1 (es) Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina.
DK0561941T3 (da) N-Substituerede lactamer anvendelige som cholecystokinin-antagonister
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
UY27109A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
PE20000127A1 (es) Derivado de bencenosulfonamida
ATE225349T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
SE9702564D0 (sv) New compounds
BR9909486A (pt) Compostos calcilìticos
ES2158840T3 (es) Nuevos analogos de adenosina carbociclicos utiles como inmunosupresores.
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
AR013152A1 (es) Derivados de 2-alquilheterodihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n.
ES2057322T3 (es) Derivados de amida de aminoacido substituidos, su fabricacion y uso.
ES2184989T3 (es) Derivados de feniletanolaminotetralincarboxamida 3,4-disustituidos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 622361

Country of ref document: ES